Tag Archives: Event

Allogene’s R&D Showcase 2022: Celltelligence Analysis – Part 1

On Tuesday, November 29, Allogene held an R&D showcase (press release / presentation) providing updated clinical milestones and results from ALLO-501A (allogeneic CD19 CAR-T) and ALLO-715 (allogeneic BCMA CAR-T). Below, Celltelligence provides insights on the new data presented by Allogene from its hematology franchise, while discussing potential regulatory timelines for ALLO-501A and how it could compete with approved autologous CAR-Ts.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.